DE Burlo Group Inc. lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 28.1% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 11,250 shares of the life sciences company’s stock after selling 4,400 shares during the period. DE Burlo Group Inc.’s holdings in Illumina were worth $2,458,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Axiom International Investors LLC DE grew its holdings in Illumina by 60.9% during the third quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock valued at $37,142,000 after purchasing an additional 70,572 shares during the period. Virtu Financial LLC bought a new position in shares of Illumina in the third quarter worth about $577,000. Creative Planning boosted its stake in shares of Illumina by 9.8% in the fourth quarter. Creative Planning now owns 12,384 shares of the life sciences company’s stock worth $2,706,000 after acquiring an additional 1,107 shares during the period. Gateway Investment Advisers LLC boosted its stake in shares of Illumina by 3.5% in the fourth quarter. Gateway Investment Advisers LLC now owns 95,711 shares of the life sciences company’s stock worth $20,912,000 after acquiring an additional 3,202 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Illumina by 4.9% in the third quarter. Schwab Charles Investment Management Inc. now owns 508,368 shares of the life sciences company’s stock worth $101,267,000 after acquiring an additional 23,647 shares during the period. 92.04% of the stock is owned by institutional investors and hedge funds.
In other Illumina news, Director Robert S. Epstein sold 1,250 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $244.18, for a total transaction of $305,225.00. Following the sale, the director now directly owns 8,588 shares in the company, valued at $2,097,017.84. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $211.35, for a total value of $4,227,000.00. Following the sale, the director now owns 531,717 shares in the company, valued at $112,378,387.95. The disclosure for this sale can be found here. Over the last three months, insiders have sold 114,440 shares of company stock valued at $25,318,904. 0.89% of the stock is owned by corporate insiders.
Illumina, Inc. (NASDAQ ILMN) opened at $220.44 on Wednesday. Illumina, Inc. has a one year low of $158.02 and a one year high of $248.97. The company has a market capitalization of $32,270.38, a P/E ratio of 44.44, a P/E/G ratio of 2.92 and a beta of 0.92. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.55 and a current ratio of 3.99.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.22. Illumina had a return on equity of 21.52% and a net margin of 26.56%. The company had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. During the same period in the prior year, the company earned $0.85 earnings per share. The firm’s revenue was up 25.7% on a year-over-year basis. equities analysts anticipate that Illumina, Inc. will post 4.59 EPS for the current year.
ILMN has been the subject of a number of recent analyst reports. Deutsche Bank raised Illumina from a “hold” rating to a “buy” rating and dropped their price objective for the stock from $195.00 to $160.00 in a research note on Monday, October 23rd. Bank of America upped their price objective on Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $229.00 price objective for the company in a research note on Friday, October 27th. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $269.00 price objective on shares of Illumina in a research note on Tuesday, January 9th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $241.39.
COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/de-burlo-group-inc-sells-4400-shares-of-illumina-inc-ilmn.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.